Third International Congress Drug Therapy in HIV Infection 3-7 November 1996 Glasgow, UK

EFFICACY OF DIFFERENT ANTIVIRAL TREATMENTS IN CYTOMEGALOVIRUS (CMV) NEUROLOGICAL COMPLICATIONS: EVALUATION BY QUANTITATIVE POLYMERASE CHAIN REACTION (PCR) ON CEREBROSPINAL FLUID (CSF).

P. Cinque¹, E. Pisa², S. Racca¹, S. Bossolasco¹, R. Marenzi¹, A. Lazzarin¹, A. Linde^3
1Infectious Diseases Dept., San Raffaele Hospital, Milan, Italy; ²AB Sangtec Medical, Bromma, Sweden; ³Virology Dept., Swedish Institute for Infectious Disease Control, Stockholm, Sweden

Int Cong Drug Therapy HIV 1996 Nov 3-7;3:Abstract No. OP3.3br /> AIDS 1996, Vol. 10 (Suppl. 2);S12

The efficacy of various antiviral treatment regimens in CMV neurological complications was evaluated using a quantitative PCR assay for the detection of CMV DNA in CSF.

30 HIV-infected patients with CMV encephalitis (CMV-E, n=26) or polyradiculomyelitis (CMV-P, n=4), received ganciclovir (GCV, 10 mg/Kg/day), foscarnet (PFA, 180 mg/Kg/day), or a combination of the two drugs. After 3 weeks of treatment, the majority of the patients with CMV-E received half-dose maintenance therapy, while 2 patients with CMV-P continued with full dose GCV.

The table shows the CMV DNA titres in the CSF (genome equivalents / ml ± S.D.) before and after 3 weeks of full dose treatment.

Clinical neurological conditions improved in 6/26 patients with CMV-E, without apparent correlation with the drugs received, and in all the 4 patients with CMV-P. After 4 weeks of maintenance therapy, CSF CMV DNA titres were elevated up to baseline levels in all the 6 evaluable patients with CMV-E, whereas they were further decreased after 5-16 weeks of full dose GCV in both patients with CMV-P. Autopsy examination confirmed CMV-E in 9/10 patients examined.

In most of patients full dose GCV or/and PFA for 3 weeks is effective in reducing CMV replication in the nervous system. The clinical neurological response, however, is poor in most of the patients with CMV-E.

Presenting author: P. Cinque

1996-11-03
OP3.3

Originally published in AIDS Volume 10, Supplement 2 and hosted with permission of the publisher Lippincott Williams & Wilkins, 250 Waterloo Road, London, SE1 8RD, UK. Tel: +44 (0)20 7981 0700 Fax: +44 (0) 7981 0701

Copyright © 1996 - Lippincott Williams & Wilkins. All rights reserved. All abstracts from the 3rd International Congress Drug Therapy in HIV Infection, appearing on the AEGiS web site, are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, or otherwise published without the prior written permission of Lippincott Williams & Wilkins. You may not alter or remove any trademark, copyright or other notice. However, provided that you maintain all copyright and other notices contained therein, you may download material (one machine readable copy and one print copy per page) for your personal, non-commercial use only.

http://www.aidsonline.com http://www.ovid.com